Cargando…

Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is seriously affecting the general health due to its high prevalence and associated risk of liver-related consequences and extrahepatic chronic complications. New drugs are urgently needed for the treatment of NAFLD. The purpose of this meta-analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Si-min, Shi, Xiao-yan, Fan, Yan-ping, Yang, Lin-lin, Yao, Jia, Feng, Pei-min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337581/ https://www.ncbi.nlm.nih.gov/pubmed/32629641 http://dx.doi.org/10.1097/MD.0000000000020695

Ejemplares similares

Efficacy and safety of Yinchenwuling Powder for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis of randomized controlled trials
por: Wu, Peishan, et al.
Publicado: (2022)

Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese
por: Huang, Xiaolin, et al.
Publicado: (2015)

Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis
por: Zhou, Xiangyu, et al.
Publicado: (2023)

Xiaochaihu decoction for nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis
por: Zhu, Wenyu, et al.
Publicado: (2021)

Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis
por: Liu, Rongqiang, et al.
Publicado: (2019)

Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Kim, Gyuri, et al.
Publicado: (2015)

Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs
por: Zhou, Haiyan, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease: A Negative Risk Factor for Colorectal Cancer Prognosis
por: You, Jie, et al.
Publicado: (2015)

Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean
por: Oh, Yun Hwan, et al.
Publicado: (2023)

Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects
por: Zhang, Shujun, et al.
Publicado: (2017)

The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials
por: Zhong, Sheng, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis
por: Sinn, Dong Hyun, et al.
Publicado: (2016)

Risk factors of nonalcoholic fatty liver disease in healthy women
por: Guan, Hui, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease as a Risk Factor of Arterial Stiffness Measured by the Cardioankle Vascular Index
por: Chung, Goh Eun, et al.
Publicado: (2015)

Visceral Adipose Tissue Area as an Independent Risk Factor for Elevated Liver Enzyme in Nonalcoholic Fatty Liver Disease
por: Chung, Goh Eun, et al.
Publicado: (2015)

Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis
por: Sawangjit, Ratree, et al.
Publicado: (2016)

Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs
por: Zhao, Yan, et al.
Publicado: (2023)

Nonalcoholic fatty liver was associated with asymptomatic gallstones in a Chinese population
por: Qiao, Qiao-Hua, et al.
Publicado: (2017)

Development of de novo nonalcoholic fatty liver disease following pancreatectomy
por: Patel, Vanisha, et al.
Publicado: (2023)

The metabolic influence of duodenal mucosal resurfacing for nonalcoholic fatty liver disease
por: Chuang, Te-Jung, et al.
Publicado: (2023)

Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: What should we expect from a meta-analysis?
por: Wei, Lin, et al.
Publicado: (2021)

Soy diet for nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials
por: Xiong, Pian, et al.
Publicado: (2021)

The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials
por: Zhou, Jingwen, et al.
Publicado: (2021)

Metabolic status indicators and influencing factors in non-obese, non-centrally obese nonalcoholic fatty liver disease
por: Huang, Zhipeng, et al.
Publicado: (2023)

Association of resting heart rate with nonalcoholic fatty liver disease in postmenopausal women
por: Kim, Hong-Bae, et al.
Publicado: (2020)

A nomogram incorporated lifestyle indicators for predicting nonalcoholic fatty liver disease
por: Peng, Kaili, et al.
Publicado: (2021)

Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis
por: Dai, Wenjie, et al.
Publicado: (2017)

Efficacy and safety of omega-3 fatty acids on liver-related outcomes in patients with nonalcoholic fatty liver disease: A protocol for a systematic review and meta-analysis
por: Shi, Xiao-yan, et al.
Publicado: (2020)

The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Candidate genes investigation for severe nonalcoholic fatty liver disease based on bioinformatics analysis
por: Qi, Shan, et al.
Publicado: (2017)

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
por: Romero-Gomez, Manuel, et al.
Publicado: (2020)

Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins
por: Pirola, Carlos J., et al.
Publicado: (2015)

The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease
por: Liang, Jing, et al.
Publicado: (2016)

Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients
por: Phisalprapa, Pochamana, et al.
Publicado: (2017)

Comparison of noninvasive scoring systems for the prediction of nonalcoholic fatty liver disease in metabolic syndrome patients
por: Saokaew, Surasak, et al.
Publicado: (2020)

Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease
por: Kawaguchi, Kazunori, et al.
Publicado: (2021)

Association between nonalcoholic fatty liver disease and colorectal cancer: A population-based study
por: Wu, Po-Hsien, et al.
Publicado: (2023)

Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review
por: Xu, Liubin, et al.
Publicado: (2022)

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease
por: Li, Qiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ccee0dc6n27pcaobugq22g9l29